Adagene Inc.
ADAGNext catalyst
ADG126
Advanced/Metastatic Solid Tumors
Get an email about ADAG's next catalysts
Track Adagene (ADAG) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (Phase 2 readout).See the timeline
3 upcoming, 0 past
ADG126 Phase 2 Est. Readout
Primary completion for ADG126 trial (NCT05405595) in Advanced/Metastatic Solid Tumors
SourceTPST-1120 Phase 2 Est. Readout
Estimated primary completion for TPST-1120 trial (NCT04524871) in Advanced Liver Cancers. Topline data typically follows completion by weeks to months.
SourceTobemstomig Phase 2 Est. Readout (MORPHEUS-LIVER)
Estimated primary completion for Tobemstomig trial (NCT04524871) in Advanced Liver Cancers. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
ADG126 Mono
Advanced/Metastatic Solid Tumors
ADG126
Advanced/Metastatic Solid Tumors
ADG106
HER2-negative Breast Cancer
TPST-1120
Advanced Liver Cancers
IO-108
Advanced Liver Cancers
Tobemstomig
Advanced Liver Cancers
NKT2152
Advanced Liver Cancers
ADG126-ADG106
Advanced/Metastatic Solid Tumors
ADG126-anti PD1
Advanced/Metastatic Solid Tumors
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ADG126 Mono | Phase 2 | Advanced/Metastatic Solid Tumors | - | - |
ADG126 | Phase 2 | Advanced/Metastatic Solid Tumors | - | - |
ADG106 | Phase 2 | HER2-negative Breast Cancer | - | - |
TPST-1120 | Phase 2 | Advanced Liver Cancers | - | - |
IO-108 | Phase 2 | Advanced Liver Cancers | - | - |
Tobemstomig | Phase 2 | Advanced Liver Cancers | - | - |
NKT2152 | Phase 2 | Advanced Liver Cancers | - | - |
ADG126-ADG106 | Phase 2 | Advanced/Metastatic Solid Tumors | - | - |
ADG126-anti PD1 | Phase 2 | Advanced/Metastatic Solid Tumors | - | - |
Frequently asked questions
What is in Adagene Inc.'s drug pipeline?→
CatalystAlert tracks 9 drug candidates in Adagene Inc.'s (ADAG) pipeline across Phase 2. Its lead program is ADG126 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Adagene Inc.'s next FDA catalyst?→
Adagene Inc.'s (ADAG) next tracked catalyst is a Phase 2 readout expected Q2 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ADAG biotech catalysts?→
Add ADAG to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Adagene Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.